Drug Trial Radar · NCT04654741
The Rate of Embryo Euploidy in Progestin-primed Ovarian Stimulation Cycles
Last checked: Nov 20, 2026Latest source record: Dec 4, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
396
Planned (sponsor's estimate)
Start
Sep 1, 2020
Primary completion
Feb 1, 2022
Study completion Dec 31, 2022
Sponsor
- Lead sponsor
- Casa di Cura Privata Villa MafaldaResearch network
- Sponsor type
- Research network
- First posted
- Dec 4, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this non-inferiority randomized controlled trial is to assess the rate of blastocyst euploidy and the number of euploid blastocysts in women undergoing IVF/ICSI and treated with PPOS versus conventional ovarian stimulation based on the use of GnRH antagonist The hypothesis is that PPOS is associated with a rate of blastocyst euploidy similar to what found with the conventional ovarian stimulation. In other words, the number of euploid blastocysts that can be obtained with the PPOS strategy is expected to be the same obtained with conventional ovarian stimulation. Moreover we expect to find non significant differences in all intermediate outcome of the IVF cycles, such as in the rate of premature LH surge, in the rate of patients with elevation of Progesterone on the triggering day, in FSH consumption and length of stimulation, in the rate of poor response and hyperresponse, in number of retrieved and mature oocytes, in fertilization and blastulation rate, in the number of available blastocysts and in the morphological quality of blastocysts
Conditions
- IVF
- Infertility
Interventions
Medroxyprogesterone AcetateDrug
1 pill per day
Ganirelix AcetateDrug
1 injection per day
Primary outcomes
What the sponsor says the trial is designed to measure.
- blastocyst euploidyTime frame: From the date of randomization up to the assessment of blastocyst euploidy (up to 20 weeks)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Villa Mafalda
Roma, Italy · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.